01. Emerging concepts / New Agents

​

P01.01. | Isoliquiritigenin attenuated metastatic development of pancreatic cancer by regulation of the tumor microenvironment and reactivation from chemoresistance

Joshua Ko, Kowloon Tong, Hong Kong

 

P01.02. | BIUX2X2

Shan Han, Heidelberg, Germany

 

P01.03. | Enhancing NK cell cytotoxicity against tumor cells with a novel self-delivering RNAi compound targeting Cbl-b

Melissa Maxwell, Marlborough, United States

 

P01.04. | Withdrawn

 

P01.05. | Withdrawn

 

P01.06. | Overcoming resistance to ICI therapy by downregulating the expression of Neuropilin-1 with antisense oligonucleotides

Richard Klar, Planegg, Germany

 

P01.07. | Intracellular and extracellular biochemical activities of V-domain Ig-containing suppressor of T cell activation or VISTA

Vadim Sumbayev, Chatham Maritime, United Kingdom

 

P01.08. | Discovery of CRD1601, a potent and selective HPK1 inhibitor with robust in vivo anti-cancer activity

Ritesh Shrivastava, Noida, India

 

P01.09. | CRD3874-SI: a novel allosteric STING agonist with high systemic tolerability

Sandip Middya, Noida, India

 

P01.10. | Real-time interaction cytometry reveals different binding kinetics of antibodies targeting membrane proteins on fixed versus living cells

Vivien Hafner, München, Germany

 

​

02. Tumor microenvironment and microbiome in Immunotherapy

 

P02.01. | Herpesvirus entry mediator - a two-way switch for immunity

jiaxin xia, Changsha City, Hunan Province, China

 

P02.02. | Spectral flow cytometry reveals immune regulation of detailed lymphocyte and myeloid populations in neuroblastoma

Anne Borst, Utrecht, Netherlands

 

P02.03. | Ready-to-use multiplex immunofluorescence assay panels provide reliable deep spatial phenotyping for immuno-oncology applications.

Arne Christians, Hannover, Germany

 

P02.04. | Withdrawn

 

P02.05. | AATF(Che-1) RNA polymerase II binding protein overexpression in BCP-ALL cells controls NK-cell proliferation through IL15 expression

Matteo Caforio, Roma, Italy

​

P02.06. | Integrated multi-omics unraveled a basal cell-dependent signature predictor of outcome and immunotherapy response in LUSC

Jianlong Jia, München, Germany

 

P02.07. | Trial in progress: Anti-PD1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): a proof-of-principle study (AuspiCiOus)

Joris Bos, Amsterdam, Netherlands

 

P02.08. | Immune-related protein changes due to standard of care therapy in recurrent ovarian cancer patients

Julie Kempeneers, Leuven, Belgium

 

P02.09. | Correlation of NK cell activity depending on TNF receptor expression on stem cells

Vladimir Jurisic, Kragujevac, Serbia

 

P02.10. | Simplifying High-Parameter Phenotypic and Functional Characterization of Cancer Immune Cells

Anne-Sophie Thomas-Claudepierre, Paris, France

 

P02.11. | 50-Parameter Flow Cytometry by CyTOF Empowers Comprehensive Single-Cell Immune Profiling of Pulmonary Immunosenescence in Aged Mice

Anne-Sophie Thomas-Claudepierre, Paris, France

 

P02.12. | Immuno-Oncology Imaging Mass Cytometry Study of the Structural and Cellular Composition of the Tumor Microenvironment in Human Cancers

Anne-Sophie Thomas-Claudepierre, Paris, France

 

P02.13. | Identifying Pathophysiological Features of Mouse Tumors Using Imaging Mass Cytometry

Anne-Sophie Thomas-Claudepierre, Paris, France

 

P02.14. | High-Plex Co-Detection of RNA and Protein to Explore Tumor-Immune Interactions Utilizing RNAscope With Imaging Mass Cytometry

Anne-Sophie Thomas-Claudepierre, Paris, France

 

03. Vaccine Therapy

 

P03.01. | Efficacy and toxicity of BCG therapy in bladder cancer

Suryakanta Acharya, Lakhimpur, India

 

P03.02. | Development of an antitumor vaccine approach based on the delivery of messenger RNA using a cell penetrating peptide

Mohammed Sebane, Strasbourg, France

 

P03.03. | Withdrawn

​

​

04. Precision Medicine Meets Immunotherapy (Immuno-Monitoring)

 

P04.01. | Early recovery of radiation induced lymphopenia in NSCLC stage III lung cancer: correlation with prognosis in a prospective study

Thomas Philipp Hofer, München, Germany

 

P04.02. | Imaging mass cytometry reveals the spatial network of immune cells in neuroblastoma

Francisca Bergsma, Utrecht, Netherlands

 

P04.03. | Immuno-Analytics of Patients with Gastric Cancer: Impact of Systemic Polychemotherapy on Peripheral T-Cell Fitness and Immunologic Features of Gastric Cancer Tissue

Anna Reischer, Munich, Germany

 

P04.04. | Single cell transcriptomics reveals cancer associated fibroblasts enable modeling of tumor associated macrophage like phenotypes and treatment responses in primary colorectal cancer organoid cultures

Julijan Kabiljo, Wien, Austria

​

P04.05. | New non-invasive, label-free monitoring approach for 2D and 3D cell culture

Anna Jötten, Munich, Germany

 

05. Immunometabolism

 

P05.01. | Sensitizing immunotherapy refractory prostate cancer with optimized ketogenic diet regimen and epigenetic reprogramming

Xin Lu, Notre Dame, United States

 

P05.02. | Investigating the kinetics of CD3 binding and trafficking in real-time

Paolo Zucchetti, Uppsala, Sweden

 

 

06. B cells in IO

 

P06.01. | Gain-of-function CARD11 signalling in B cells causes pathological lymphoproliferative disease in mice which is strictly dependent on MALT1 activity

Andreas Kratzert, Munich, Germany

 

P06.02. | Spatio-functional Characterization of Tumor-infiltrating B cells in the Tumor Microenvironment of Cutaneous T cell Lymphoma

Sabine Oganesian, Munich, Germany

 

P06.03. | Withdrawn

 

 

08. Local IO

 

P08.01. | Novel approaches for investigating LAG3 mechanisms of action

Sara Bodbin, Uppsala, Sweden

 

 

09. Cell Therapy in Solid Tumors

 

P09.01. | Adapting immune cells to the hypoglycemic tumor microenvironment by solute carrier 2a1 (Slc2a1/GLUT1) overexpression

Martin Kirmaier, Munich, Germany

 

P09.02. | Loading of CAR-T cells with superparamagnetic iron oxide nanoparticles allows their magnetic targeting for local induction of antigen-specific anti-tumor responses

Felix Pfister, Erlangen, Germany

 

P09.03. | Loading of T cells with superparamagnetic iron oxide nanoparticles gives them magnetic controllability while retaining antigen-specific effector functions

Lucas Carnell, Erlangen, Germany

 

P09.04. | Isolation of a high avidity TCR targeting a newly identified epitope of a common cancer testis antigen expressed by solid tumors

Emina Sivro, Berlin, Germany

 

P09.05. | Novel A20 based therapeutic strategies to fight lung cancer

Monika Homolya, Vienna, Austria

 

P09.06. | Establishing a mouse model to visualize limitations of CAR-T cells activity in solid tumors

Baptiste Arnaud, Paris, France

 

P09.07. | Determining potency, activation and expansion of antigen specific T cells

B. Hansen, Virum, Denmark

 

 

10. Cell Therapy in Haematologic Diseases

 

P10.01. | Nutritional and immunometabolic measures for risk assessment in allogeneic hematopoietic stem cell transplantation

Hannah Thurisch, München, Germany

 

 

11. Combination Therapy

 

P11.01. | Oncological outcomes of laparoscopic versus open radical total gastrectomy for upper-middle gastric cancer after neoadjuvant chemotherapy

Shen Li-LI, Fuzhou, China

 

P11.02. | A complex human tumor organoid model consisting of malignant cells, fibroblasts and immune cells enlights the effect of chemotherapy-induced senescent tumor cells on NK-cell anti-tumor responses

Daphni Ammon, Vienna, Austria

 

 

12.Young Researchers Session

 

P12.01. | Utilizing radiation to improve adoptive cell therapy with tumor infiltrating lymphocytes

Nina Obertopp, Tampa, United States

 

P12.02. | Adaptor P329G-directed CAR T cells for modular targeting of AML

Sophia Stock, Munich, Germany

 

P12.03. | Heterotypic CD8 T cell clusters isolated from clinical samples are distinct and enriched for antitumor activity

Sofía Ibáñez Molero, Amsterdam, Netherlands

 

P12.04. | Adherence to clinical guidelines for managing febrile neutropenia inpatients undergoing hematopoietic stem cell transplantation: Are weinclined to follow the recommendations of IDSA and NCCN in LMIC?

Kashif Ali, Karachi, Pakistan

 

P12.05. | Cellular biosensors to study protein interactions relevant to immunotherapy

Maximilian Funk, Munich, Germany

 

P12.06. | GLP-compliant validation of a FluoroSpot assay to monitor tumor neoantigen vaccinations in preclinical mouse models

Alexandra Mauthe, Straßberg, Germany

 

P12.07. | AI-enhanced quantitative assessment of T cell cytotoxicity using label-free live-cell imaging on micro-pattern for high-throughput investigation of T cell quality and moderation by tumor microenvironment

Jincheng Cao, München, Germany

 

P12.08. | Targeting tumor-reduced drug accessibility to counteract organ-specific resistance to anti-CD22 immunotoxins

Franziska Gsottberger, Erlangen, Germany

 

P12.09. | Expanded T cell clones in neuroblastoma persist throughout chemotherapy and display a druggable dysfunctional profile

Elisa Zappa, Utrecht, Netherlands

 

P12.10. | In vivo dynamics and anti-tumor effects of B7-H3-directed CAR T-cells in an orthotopic medulloblastoma mouse model

Julika Herold, München, Germany

 

P12.11. | RECQL4 promotes immune evasion and limits response to anti-PD-1 therapy and survival in melanoma patients

Sara Egea-Rodriguez, Munich, Germany

 

P12.12. | The tumor microenvironment of epithelial ovarian cancer: exhausted and immunosuppressive

Alexandra Leutbecher, Munich, Germany